<DOC>
	<DOCNO>NCT02601313</DOCNO>
	<brief_summary>Study KTE-C19-102 phase 2 , multicenter , open-label study evaluate efficacy KTE-C19 subject Relapsed/Refractory MCL</brief_summary>
	<brief_title>A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<criteria>Key Pathologically confirm MCL Up 5 prior regimen MCL . Prior therapy must include : Anthracycline bendamustinecontaining chemotherapy AntiCD20 monoclonal antibody therapy Ibrutinib Relapsed refractory disease , define follow : Disease progression last regimen , Refractory disease define failure achieve PR CR last regimen At least 1 measurable lesion accord revise IWG Response Criteria Malignant Lymphoma Age 18 year old Eastern cooperative oncology group ( ECOG ) performance status 0 1 ANC ≥ 1000/µL Platelet count ≥ 50,000/µL Adequate renal , hepatic , cardiac function define : Serum creatinine ≤ 1.5 mg/dL Serum ALT/AST ≤ 2.5 ULN Total bilirubin ≤ 1.5 mg/dL , except subject Gilbert 's syndrome . Cardiac ejection fraction ≥ 50 % ( ECHO ) evidence pericardial effusion determine ECHO . Key History malignancy nonmelanomatous skin cancer carcinoma situ ( e.g . cervix , bladder , breast ) unless disease free least 3 year History allogeneic stem cell transplantation Prior CD19 target therapy Prior CAR therapy genetically modify T cell therapy Known history infection HIV hepatitis B ( HBsAg positive ) hepatitis C virus ( antiHCV positive ) Subjects detectable cerebrospinal fluid malignant cell brain metastasis history cerebrospinal fluid malignant cell brain metastasis History seizure disorder , cerebrovascular ischemia/hemorrhage , dementia , cerebellar disease , autoimmune disease CNS involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>